STC2 and esophageal squamous cell carcinoma: Further clinicopathological analyses demonstrated STC2 levels are correlated with lymphatic invasion, lymph node metastasis, and poor prognosis in ESCC patients, suggesting STC2 is a potential biomarker and a therapeutic target for ESCC.